Intracameral Levofloxacin (0.5%) vs Intracameral Cefuroxime
NCT ID: NCT04212078
Last Updated: 2020-09-21
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
UNKNOWN
Clinical Phase
PHASE1/PHASE2
Total Enrollment
138 participants
Study Classification
INTERVENTIONAL
Study Start Date
2019-07-29
Study Completion Date
2022-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Endophthalmitis is a clinical diagnosis made when intraocular inflammation involving both posterior and anterior chamber; is attributable to bacterial or fungal infection. It is a serious intraocular inflammatory disorder which can be spread via endogenous or exogenous access into the eye by infecting organism. Exogenous spread usually happens post intraocular surgery or procedure (i.e. cataract, vitrectomy, glaucoma filtration surgery) while endogenous spread is associated with hematogenous spread. The occurrence of endophthalmitis accounts for serious post-operative complication which can lead to severe vision loss and even blindness. There are several studies conducted to ascertain the efficiency of intracameral antibiotic as post-operative endophthalmitis prophylaxis. However, there is limited study in human using intracameral levofloxacin to evaluate its effect.This study is designed to compare between intracameral levofloxacin and intracameral cefuroxime in terms of corneal endothelial cell count and its morphology and central corneal thickness in uncomplicated phacoemulsification surgery
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Pharmacokinetics of Topical Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%
NCT04214821
Endophthalmitis
UNKNOWN
PHASE1/PHASE2
The Clinical Safety of Levofloxacin 1.5% vs Topical Moxifloxacin 0.5%
NCT04212429
Endophthalmitis Postoperative
UNKNOWN
PHASE1/PHASE2
To Compare the Safety and Efficacy of Intracameral Levofloxacin and Intracameral Cefazolin in Reducing Rates of Endophthalmitis Following Cataract Surgery.
NCT06710977
Cataract
COMPLETED
EARLY_PHASE1
Effectiveness of Topical 0.5% Levofloxacin to Reduce the Conjunctival Bacterial Flora Before Intraocular Surgery
NCT00491049
Conjunctival Bacterial Flora
COMPLETED
PHASE4
Postoperative Safety Outcomes of Intraoperative Intracameral Preservative-Free Moxifloxacin Versus Levofloxacin
NCT04403334
Cataract Senile
Endophthalmitis
Antibiotic Side Effect
+1 more
COMPLETED
PHASE4
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This is a prospective, double - blinded randomized clinical trial conducted in University Kebangsaan Malaysia Medical Centre (UKMMC). All patients from Ophthalmology Clinic in UKM Medical Centre from December 2018 till June 2021 will be involved in this study. Patients who fulfill the inclusion criteria will be included in this study.
Preoperative assessment includes proper history taking and ocular examinations.Ocular examination includes baseline visual acuity, slit lamp examinations to ascertain the cataract grading, anterior chamber reactions preoperatively, intraocular pressure measurement via applanation tonometry and fundus examinations using 78D condensing lens. Cornea endothelial examinations will be done by using non-contact TOPCON Specular Microscopy model SP-1P.
On the day of surgery, patients will be informed about the two different antibiotics available that will be used at the end of cataract surgery. A written informed consent will be obtained from the patient.
Patients will be randomized before entering the operating theatre. Sealed envelopes total of 4 will be prepared by the researcher; 2 of which will be labelled as A and another 2 envelopes will be labelled as B. The researcher will randomly pick 1 envelope and allocate to patient's file. The staff nurse in charge will then open the envelope, label A or B will then be pasted on the patient's file (rear part) for documentation.
Cataract surgery will be performed byusing Centurion®Vision System, Alcon, Texas, United Stated of America (USA) phacoemulsification machine. 0.3 ml of levofloxacin 0.5% ophthalmic solution (Cravit®, Santen) will be syringed out and at the conclusion of cataract surgery, the solution of 0.1ml which has 0.5 mg levofloxacin will be injected via intracameral into the anterior chamber through the side port wound using a tuberculin syringe in a 27 gauge cannula.
On the other hand, at the beginning part of surgery, cefuroxime will be diluted by the researcher. In order to reduce dilution error and contamination, dilution will be done strictly according to a standardised protocol that was obtained from Malaysian Clinical Practice Guideline. The vial contains 750 mg of cefuroxime powder is diluted with 7.5 ml of Balanced Salt Solution (BSS). 1 ml of the solution will be withdrawn and added with 9 ml of BSS. Then, 0.1 ml of solution which is equivalent to 1 mg of cefuroxime will be aspirated and kept a side. Then the antibiotic of 0.1 ml will be given as intracameral to patient using a tuberculin syringe in a 27 gauge cannula at side port wound at the end of surgery. The side port wound will then be sealed by stromal hydration and checked for water tightness.
This will be followed by instillation of topical guttae ciprofloxacin 0.3% (Ciloxan, Alcon) and guttae dexamethasone 0.1% (Maxidex, Alcon) and eye shield will be applied before leaving the operating theatre.
Patient will be reviewed again after 2 hours post operatively at the slit lamp and eye drops guttae ciprofloxacin 0.3% and guttae dexamethasone 0.1% will be instilled every 2 hours (5 minutes apart from one eye drop to another) for the first one week post-surgery. Upon discharge, patient will be reviewed again in eye clinic after 1 week and during this visit, these eye drops will then be tapered to 4 hourly for two weeks then six hourly for two weeks until next review. After one month the eye drops will be discontinued.
Patients will then be reviewed after one week, one month and three months post operation. During each visit, patient will be examined under slit lamp to look for anterior chamber reaction and to measure intraocular pressure. They will undergo specular microscopy examination to assess cornea endothelial cell count and morphology and central cornea thickness.
Preoperative assessment includes proper history taking and ocular examinations.Ocular examination includes baseline visual acuity, slit lamp examinations to ascertain the cataract grading, anterior chamber reactions preoperatively, intraocular pressure measurement via applanation tonometry and fundus examinations using 78D condensing lens. Cornea endothelial examinations will be done by using non-contact TOPCON Specular Microscopy model SP-1P.
On the day of surgery, patients will be informed about the two different antibiotics available that will be used at the end of cataract surgery. A written informed consent will be obtained from the patient.
Patients will be randomized before entering the operating theatre. Sealed envelopes total of 4 will be prepared by the researcher; 2 of which will be labelled as A and another 2 envelopes will be labelled as B. The researcher will randomly pick 1 envelope and allocate to patient's file. The staff nurse in charge will then open the envelope, label A or B will then be pasted on the patient's file (rear part) for documentation.
Cataract surgery will be performed byusing Centurion®Vision System, Alcon, Texas, United Stated of America (USA) phacoemulsification machine. 0.3 ml of levofloxacin 0.5% ophthalmic solution (Cravit®, Santen) will be syringed out and at the conclusion of cataract surgery, the solution of 0.1ml which has 0.5 mg levofloxacin will be injected via intracameral into the anterior chamber through the side port wound using a tuberculin syringe in a 27 gauge cannula.
On the other hand, at the beginning part of surgery, cefuroxime will be diluted by the researcher. In order to reduce dilution error and contamination, dilution will be done strictly according to a standardised protocol that was obtained from Malaysian Clinical Practice Guideline. The vial contains 750 mg of cefuroxime powder is diluted with 7.5 ml of Balanced Salt Solution (BSS). 1 ml of the solution will be withdrawn and added with 9 ml of BSS. Then, 0.1 ml of solution which is equivalent to 1 mg of cefuroxime will be aspirated and kept a side. Then the antibiotic of 0.1 ml will be given as intracameral to patient using a tuberculin syringe in a 27 gauge cannula at side port wound at the end of surgery. The side port wound will then be sealed by stromal hydration and checked for water tightness.
This will be followed by instillation of topical guttae ciprofloxacin 0.3% (Ciloxan, Alcon) and guttae dexamethasone 0.1% (Maxidex, Alcon) and eye shield will be applied before leaving the operating theatre.
Patient will be reviewed again after 2 hours post operatively at the slit lamp and eye drops guttae ciprofloxacin 0.3% and guttae dexamethasone 0.1% will be instilled every 2 hours (5 minutes apart from one eye drop to another) for the first one week post-surgery. Upon discharge, patient will be reviewed again in eye clinic after 1 week and during this visit, these eye drops will then be tapered to 4 hourly for two weeks then six hourly for two weeks until next review. After one month the eye drops will be discontinued.
Patients will then be reviewed after one week, one month and three months post operation. During each visit, patient will be examined under slit lamp to look for anterior chamber reaction and to measure intraocular pressure. They will undergo specular microscopy examination to assess cornea endothelial cell count and morphology and central cornea thickness.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Endophthalmitis Postoperative
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
PARALLEL
Primary Study Purpose
PREVENTION
Blinding Strategy
QUADRUPLE
Participants
Caregivers
Investigators
Outcome Assessors
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A-Levofloxacin
0.1 ml/0.5mg of levofloxacin 0.5% ophthalmic solution
Group Type
ACTIVE_COMPARATOR
Levofloxacin Ophthalmic
Intervention Type
DRUG
0.1ml which has 0.5 mg levofloxacin will be injected via intracameral into the anterior chamber through the side port wound using a tuberculin syringe in a 27 gauge cannula.
B-Intracameral Cefuroxime
0.1 ml/1mg of Cefuroxime
Group Type
ACTIVE_COMPARATOR
Cefuroxime
Intervention Type
DRUG
The vial contains 750 mg of cefuroxime powder is diluted with 7.5 ml of Balanced Salt Solution (BSS). 1 ml of the solution will be withdrawn and added with 9 ml of BSS. Then, 0.1 ml of solution which is equivalent to 1 mg of cefuroxime will be aspirated and kept a side. The dissolution of the antibiotic is confirmed by naked eye. Then the antibiotic of 0.1 ml will be given as intracameral to patient using a tuberculin syringe in a 27 gauge cannula at side port wound at the end of surgery.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Levofloxacin Ophthalmic
0.1ml which has 0.5 mg levofloxacin will be injected via intracameral into the anterior chamber through the side port wound using a tuberculin syringe in a 27 gauge cannula.
Intervention Type
DRUG
Cefuroxime
The vial contains 750 mg of cefuroxime powder is diluted with 7.5 ml of Balanced Salt Solution (BSS). 1 ml of the solution will be withdrawn and added with 9 ml of BSS. Then, 0.1 ml of solution which is equivalent to 1 mg of cefuroxime will be aspirated and kept a side. The dissolution of the antibiotic is confirmed by naked eye. Then the antibiotic of 0.1 ml will be given as intracameral to patient using a tuberculin syringe in a 27 gauge cannula at side port wound at the end of surgery.
Intervention Type
DRUG
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Cravit 0.5%
Zinacef
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All patients with senile cataract and age 50 - 80 years
Exclusion Criteria
* Patients with cataract other than senile cataract (e.g. traumatic cataract)
* Patients with underlying cornea disease (e.g. cornea dystrophy)
* Patients with corneal endothelial disease/endothelial cell count less than 1000/sqmm².
* Patients with intraoperative complications such as posterior capsule rupture/ prolapsed iris/ zonulysis/ anterior vitreous loss.
* Cataract grading nucleosclerosis (NS) 2+ and below.
* Patients with underlying cornea disease (e.g. cornea dystrophy)
* Patients with corneal endothelial disease/endothelial cell count less than 1000/sqmm².
* Patients with intraoperative complications such as posterior capsule rupture/ prolapsed iris/ zonulysis/ anterior vitreous loss.
* Cataract grading nucleosclerosis (NS) 2+ and below.
Minimum Eligible Age
50 Years
Maximum Eligible Age
80 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Santen Pharmaceutical Co., Ltd.
INDUSTRY
Sponsor Role
collaborator
National University of Malaysia
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wan Haslina Wan Abdul Halim
Consultant Ophthalmologist-Cornea And Anterior Segment
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wan Haslina Wan Abdul Halim, M.D
Role: STUDY_CHAIR
Department of Ophthalmology, UKM Medical Centre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UKM Medical Centre
Kuala Lumpur, Kuala Lumpur, Malaysia
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Malaysia
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Kernt M, Kampik A. Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives. Clin Ophthalmol. 2010 Mar 24;4:121-35. doi: 10.2147/opth.s6461.
Reference Type
BACKGROUND
Lee MY, Goh PP, Salowi MA, Adnan TH, Ismail M. The Malaysian Cataract Surgery Registry: Cataract Surgery Practice Pattern. Asia Pac J Ophthalmol (Phila). 2014 Nov-Dec;3(6):343-7. doi: 10.1097/APO.0000000000000030.
Reference Type
BACKGROUND
Lockington D, Flowers H, Young D, Yorston D. Assessing the accuracy of intracameral antibiotic preparation for use in cataract surgery. J Cataract Refract Surg. 2010 Feb;36(2):286-9. doi: 10.1016/j.jcrs.2009.08.034.
Reference Type
BACKGROUND
Espiritu CR, Caparas VL, Bolinao JG. Safety of prophylactic intracameral moxifloxacin 0.5% ophthalmic solution in cataract surgery patients. J Cataract Refract Surg. 2007 Jan;33(1):63-8. doi: 10.1016/j.jcrs.2006.09.019.
Reference Type
BACKGROUND
Endophthalmitis Study Group, European Society of Cataract & Refractive Surgeons. Prophylaxis of postoperative endophthalmitis following cataract surgery: results of the ESCRS multicenter study and identification of risk factors. J Cataract Refract Surg. 2007 Jun;33(6):978-88. doi: 10.1016/j.jcrs.2007.02.032.
Reference Type
BACKGROUND
Montan PG, Wejde G, Setterquist H, Rylander M, Zetterstrom C. Prophylactic intracameral cefuroxime. Evaluation of safety and kinetics in cataract surgery. J Cataract Refract Surg. 2002 Jun;28(6):982-7. doi: 10.1016/s0886-3350(01)01270-6.
Reference Type
BACKGROUND
Friling E, Lundstrom M, Stenevi U, Montan P. Six-year incidence of endophthalmitis after cataract surgery: Swedish national study. J Cataract Refract Surg. 2013 Jan;39(1):15-21. doi: 10.1016/j.jcrs.2012.10.037.
Reference Type
BACKGROUND
Raen M, Sandvik GF, Drolsum L. Endophthalmitis following cataract surgery: the role of prophylactic postoperative chloramphenicol eye drops. Acta Ophthalmol. 2013 Mar;91(2):118-22. doi: 10.1111/j.1755-3768.2011.02324.x. Epub 2011 Dec 13.
Reference Type
BACKGROUND
Shahraki K, Fard MNA, Shahri F, Pourmatin R, Mohammadi T, Boroumand PG, Shahraki K. Effects of intracameral cefuroxime on corneal endothelial cell counts and its morphology after cataract surgery. Interv Med Appl Sci. 2017 Jun;9(2):100-104. doi: 10.1556/1646.9.2017.2.13.
Reference Type
BACKGROUND
Cakir B, Celik E, Aksoy NO, Bursali O, Ucak T, Bozkurt E, Alagoz G. Toxic anterior segment syndrome after uncomplicated cataract surgery possibly associated with intracamaral use of cefuroxime. Clin Ophthalmol. 2015 Mar 17;9:493-7. doi: 10.2147/OPTH.S74249. eCollection 2015.
Reference Type
BACKGROUND
Louis B.Cantor, Christopher J. Rapuano, George A. Cioffi. Basic and Clinical Science Course. Section 9: Intraocular inflammation and uveitis. American Academy of Ophthalmology 2014-2015;8;261.
Reference Type
BACKGROUND
Management of Post-operative Infectious Endophthalmitis. Clinical Practice Guideline. August 2006. Ministry of Health Malaysia.
Reference Type
BACKGROUND
Matsuura K, Miyoshi T, Suto C, Akura J, Inoue Y. Efficacy and safety of prophylactic intracameral moxifloxacin injection in Japan. J Cataract Refract Surg. 2013 Nov;39(11):1702-6. doi: 10.1016/j.jcrs.2013.05.036. Epub 2013 Sep 18.
Reference Type
BACKGROUND
Mather R, Karenchak LM, Romanowski EG, Kowalski RP. Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002 Apr;133(4):463-6. doi: 10.1016/s0002-9394(02)01334-x.
Reference Type
BACKGROUND
Kim SY, Park YH, Lee YC. Comparison of the effect of intracameral moxifloxacin, levofloxacin and cefazolin on rabbit corneal endothelial cells. Clin Exp Ophthalmol. 2008 May;36(4):367-70. doi: 10.1111/j.1442-9071.2008.01771.x.
Reference Type
BACKGROUND
Kanda Y, Kayama T, Okamoto S, et al. A post-marketing surveillance of 0.5% levofloxacin ophthalmic solution for external ocular infections [in Japanese]. Rinsho Ganka 2008; 62 (13): 2007-17.
Reference Type
BACKGROUND
Pea F, Ferrari E, Pavan F, Roman-Pognuz D, Bandello F, Furlanut M. Levofloxacin disposition over time in aqueous humor of patients undergoing cataract surgery. Antimicrob Agents Chemother. 2005 Jun;49(6):2554-7. doi: 10.1128/AAC.49.6.2554-2557.2005.
Reference Type
BACKGROUND
Keating GM. Levofloxacin 0.5% ophthalmic solution: a review of its use in the treatment of external ocular infections and in intraocular surgery. Drugs. 2009 Jun 18;69(9):1267-86. doi: 10.2165/00003495-200969090-00009.
Reference Type
BACKGROUND
Matsuura K, Mori T, Miyamoto T, Suto C, Saeki Y, Tanaka S, Kawamura H, Ohkubo S, Tanito M, Inoue Y. Survey of Japanese ophthalmic surgeons regarding perioperative disinfection and antibiotic prophylaxis in cataract surgery. Clin Ophthalmol. 2014 Sep 29;8:2013-8. doi: 10.2147/OPTH.S64756. eCollection 2014.
Reference Type
BACKGROUND
Choi JA, Chung SK. Safety of intracameral injection of gatifloxacin, levofloxacin on corneal endothelial structure and viability. J Ocul Pharmacol Ther. 2009 Oct;25(5):425-31. doi: 10.1089/jop.2009.0010.
Reference Type
BACKGROUND
Espiritu CRG, Bolinao JG. Prophylactic intracameral levofloxacin in cataract surgery - an evaluation of safety. Clin Ophthalmol. 2017 Dec 12;11:2199-2204. doi: 10.2147/OPTH.S144625. eCollection 2017.
Reference Type
BACKGROUND
Louis B.Cantor, Christopher J. Rapuano, George A. Cioffi. Basic and Clinical Science Course. Section 8: External Disease and Cornea. American Academy of Opthalmology 2016-2017; 1; 6-9.
Reference Type
BACKGROUND
Louis B.Cantor, Christopher J. Rapuano, George A. Cioffi. Basic and Clinical Science Course. Section 11: Lens and Cataract. American Academy of Ophthalmology 2014-2015; 8; 146-151.
Reference Type
BACKGROUND
Duman R, Tok Cevik M, Gorkem Cevik S, Duman R, Perente I. Corneal endothelial cell density in healthy Caucasian population. Saudi J Ophthalmol. 2016 Oct-Dec;30(4):236-239. doi: 10.1016/j.sjopt.2016.10.003. Epub 2016 Nov 2.
Reference Type
BACKGROUND
Ganekal S, Nagarajappa A. Comparison of morphological and functional endothelial cell changes after cataract surgery: phacoemulsification versus manual small-incision cataract surgery. Middle East Afr J Ophthalmol. 2014 Jan-Mar;21(1):56-60. doi: 10.4103/0974-9233.124098.
Reference Type
BACKGROUND
Reuschel A, Bogatsch H, Barth T, Wiedemann R. Comparison of endothelial changes and power settings between torsional and longitudinal phacoemulsification. J Cataract Refract Surg. 2010 Nov;36(11):1855-61. doi: 10.1016/j.jcrs.2010.06.060.
Reference Type
BACKGROUND
Liu Y, Zeng M, Liu X, Luo L, Yuan Z, Xia Y, Zeng Y. Torsional mode versus conventional ultrasound mode phacoemulsification: randomized comparative clinical study. J Cataract Refract Surg. 2007 Feb;33(2):287-92. doi: 10.1016/j.jcrs.2006.10.044.
Reference Type
BACKGROUND
Walkow T, Anders N, Klebe S. Endothelial cell loss after phacoemulsification: relation to preoperative and intraoperative parameters. J Cataract Refract Surg. 2000 May;26(5):727-32. doi: 10.1016/s0886-3350(99)00462-9.
Reference Type
BACKGROUND
Storr-Paulsen A, Norregaard JC, Farik G, Tarnhoj J. The influence of viscoelastic substances on the corneal endothelial cell population during cataract surgery: a prospective study of cohesive and dispersive viscoelastics. Acta Ophthalmol Scand. 2007 Mar;85(2):183-7. doi: 10.1111/j.1600-0420.2006.00784.x.
Reference Type
BACKGROUND
Hayashi K, Hayashi H, Nakao F, Hayashi F. Risk factors for corneal endothelial injury during phacoemulsification. J Cataract Refract Surg. 1996 Oct;22(8):1079-84. doi: 10.1016/s0886-3350(96)80121-0.
Reference Type
BACKGROUND
Chang A, Fridberg A, Kugelberg M. Comparison of phacoemulsification cataract surgery with low versus standard fluidic settings and the impact on postoperative parameters. Eur J Ophthalmol. 2017 Jan 19;27(1):39-44. doi: 10.5301/ejo.5000813. Epub 2016 May 31.
Reference Type
BACKGROUND
Hasegawa Y, Nejima R, Mori Y, Sakisaka T, Minami K, Miyata K, Oshika T. Risk factors for corneal endothelial cell loss by cataract surgery in eyes with pseudoexfoliation syndrome. Clin Ophthalmol. 2016 Aug 30;10:1685-9. doi: 10.2147/OPTH.S106661. eCollection 2016.
Reference Type
BACKGROUND
Doerte Luensmann. The Endothelium - What Difference do SiH Lenses Make? High-Dk silicone Hydrogel lenses. May 2010.
Reference Type
BACKGROUND
Chylack LT Jr, Wolfe JK, Singer DM, Leske MC, Bullimore MA, Bailey IL, Friend J, McCarthy D, Wu SY. The Lens Opacities Classification System III. The Longitudinal Study of Cataract Study Group. Arch Ophthalmol. 1993 Jun;111(6):831-6. doi: 10.1001/archopht.1993.01090060119035.
Reference Type
BACKGROUND
The Standardisation of Uveitis Nomenclature (SUN) Working Group. Grading Scheme for Anterior Chamber Cells.
Reference Type
BACKGROUND
Julious SA. Sample sizes for clinical trials with normal data. Stat Med. 2004 Jun 30;23(12):1921-86. doi: 10.1002/sim.1783.
Reference Type
BACKGROUND
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FF-2019-133
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Levofloxacin Ocular Implant for Ocular Surgery
NCT04682288
COMPLETED
PHASE1
Ocular Tissue Levels of 1.5% Levofloxacin Ophthalmic Solution Compared to an Active Comparator
NCT00630019
COMPLETED
PHASE4
Study of Antibiotic Prophylaxis for Endophthalmitis Following Cataract Surgery
NCT00136344
COMPLETED
NA
Study of DE-108 Ophthalmic Solution in Patients Who Are Scheduled for Cataract Surgery
NCT02573610
COMPLETED
PHASE3
Evaluation Of Aqueous Humor Of Levofloxacin-Dexamethasone Eye Drops And Of Its Components In Patients Undergoing Cataract Surgery
NCT03740659
COMPLETED
PHASE2
Penetrance of Third Generation Fluoroquinolones in Eyes With Functioning Filtering Blebs
NCT00392275
COMPLETED
PHASE4
Optimization of Sampling and Processing of Samples for Molecular Microbial Research on Ocular Surface Samples
NCT04193774
COMPLETED
NA
Safety Profile Comparison of Undiluted Intracameral Moxifloxacin vs. Levofloxacin in Cataract Surgery
NCT05741632
COMPLETED
PHASE1
Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery
NCT00645671
COMPLETED
PHASE3
The Effect of Intracameral Cefuroxime on Post-op Fibrin in Pediatric Cataract Surgery
NCT00730938
COMPLETED
NA
LE Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
NCT02786901
COMPLETED
PHASE3
Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery
NCT00699153
COMPLETED
PHASE3
Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery
NCT03739528
COMPLETED
PHASE3
Loteprednol Etabonate Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
NCT02208297
COMPLETED
PHASE3
Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis
NCT02595359
COMPLETED
PHASE2
Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
NCT01060072
COMPLETED
PHASE3
Evaluation of Efficacy and Safety of Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis.
NCT02770729
TERMINATED
PHASE3
Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery
NCT00335231
WITHDRAWN
NA
Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
NCT01010633
COMPLETED
PHASE3
Acular LS vs. Nevanac in Post op Inflammation Following Cataract Surgery
NCT00348582
COMPLETED
PHASE4
Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients: Trough Drug Effects
NCT00469690
COMPLETED
PHASE4
Aqueous Concentrations and PGE2 Inhibition of Ketorolac 0.4% vs. Bromfenac 0.09% in Cataract Patients
NCT00347503
COMPLETED
PHASE4
Loteprednol vs Prednisolone for the Treatment of Intraocular Inflammation Following Cataract Surgery in Children.
NCT01475643
COMPLETED
PHASE3
A Comparison of Post Phacoemulsification Aqueous Flare in Patients Using Ketorolac 0.45% 2 Times Daily (BID) and Bromfenac 0.09% 2 Times Daily (BID)
NCT01023724
COMPLETED
PHASE4
Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation
NCT00433225
COMPLETED
PHASE4